drugset / Trial / NCT00828971

A Study to Assess Efficacy and Safety of IV/PO Moxifloxacin in the Treatment of cSSSIs

NCT00828971

Phase 3 Completed 16 enrolled Bayer
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to assess if a therapy with intravenous and oral moxifloxacin is as effective as a therapy with intravenous and oral amoxicilline/clavulanate in the treatment of complicated skin and skin structure infection.

Timeline

Start
2008-11
Primary completion
2009-09
Completion
2009-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Amoxicillin Other / unclassified 875 mg Intravenous
Subject Moxifloxacin Small molecule 400 mg Intravenous
Comparator clavulanic acid Small molecule 125 mg Intravenous

Indications